Company Overview and News

 
PRG, Hiap Teck, Lion Corp, Berjaya Media, ConnectCounty, Sunway REIT, Crescendo, Tanjung Offshore, and NPC Resources

2016-09-29 theedgemarkets
KUALA LUMPUR (Sept 29): Based on corporate announcements and news flow today, companies that may be in focus tomorrow (Sept 30) could include the following: PRG, Hiap Teck, Lion Corp, Berjaya Media, ConnectCounty, Sunway REIT, Crescendo, Tanjung Offshore, and NPC Resources.   PRG Holdings Bhd, which is involved in manufacturing, property development and construction businesses, is considering listing its manufacturing business on the Growth Enterprise Market of the Stock Exchange of Hong Kong Ltd (HKEX).

 
KLCI drops 0.54%, banking stocks weigh

2016-08-03 theedgemarkets
KUALA LUMPUR (Aug 3): The FBM KLCI dropped 0.54% at the midday break today as sentiment stayed tepid in line with the fall at most regional markets, weighed by index-linked banking stocks.

 
AE Multi rises 3.45% on renewable energy venture plan

2016-06-17 www2.theedgemarkets
KUALA LUMPUR (June 17): AE Multi Holdings Bhd shares rose 3.45% this morning after it entered into an agreement with JMT Kelantan Baru Sdn Bhd, which will pave the way for it to venture into the growing renewable energy industry.

 
KLCI expected to come under pressure to go lower

2016-06-16 www2.theedgemarkets
KUALA LUMPUR (June 17): The market is expected to come under pressure to go lower today with immediate support at seen 1,611 points for the FBM KLCI.

 
AE Multi Holdings, MB World Group, DKSH Holdings, Lion Corp, AmanahRaya REIT, Brite-Tech, Sunway, Reach Energy, KNM Group, Press Metal, Mudajaya and Mah Sing

2016-06-16 www2.theedgemarkets
KUALA LUMPUR (June 16): Based on corporate announcements and news flow today, companies that might be in focus tomorrow (Friday, June 17) include: AE Multi Holdings Bhd, MB World Group, DKSH Holdings, Lion Corp, AmanahRaya REIT, Brite-Tech, Sunway, Reach Energy, KNM Group, Press Metal, Mudajaya Group and Mah Sing Group.

 
KLCI edges higher, supported by local funds

2016-06-06 www2.theedgemarkets
KUALA LUMPUR (June 6): The FBM KLCI edged up higher by 12.53 points or 0.77%, supported by local funds, as the ringgit strengthened to 4.0985 against the US dollar after ranging between 4.08 and 4.136 throughout the day.

 
Bursa Malaysia remains higher at mid-afternoon

2016-06-06 themalaymailonline
An investor monitors share market prices at a brokerage firm in Kuala Lumpur, Malaysia, August 24, 2015. — Reuters picKUALA LUMPUR, June 6 — Bursa Malaysia remained higher at mid-afternoon today, but gains were capped by losses in selected heavyweights, dealers said. 

 
KL shares higher at the break

2016-06-03 themalaymailonline
KUALA LUMPUR, June 3 — The FTSE Bursa Malaysia KLCI (FBM KLCI) was higher as the morning session ended, supported by emerging buying momentum in selected heavyweight counters, dealers said.

 
KL shares remain higher at mid-morning

2016-06-03 themalaymailonline
KUALA LUMPUR, June 3 ― Shares on Bursa Malaysia remained higher at mid-morning today, prompted by renewed buying support for selected heavyweights, dealers said.

 
KL shares open higher to extend gains

2016-06-03 themalaymailonline
KUALA LUMPUR, June 3 — Share prices on Bursa Malaysia extended its gains to open higher today on continued buying momentum in selected heavyweights, dealers said.

 
Bursa shares rebound slightly at mid-morning

2016-06-02 themalaymailonline
An investor monitors share market prices at a brokerage firm in Kuala Lumpur, Malaysia, August 24, 2015. — Reuters picKUALA LUMPUR, June 2 — Shares on Bursa Malaysia rebounded slightly at mid-morning today, prompted by mild buying support for selected heavyweights, dealers said.

 
KL shares open lower for fourth consecutive day

2016-06-02 themalaymailonline
An investor monitors share market prices at a brokerage firm in Kuala Lumpur, Malaysia, August 24, 2015. — Reuters picKUALA LUMPUR, June 2 — Share prices on Bursa Malaysia opened lower for the fourth consecutive day on continued selling activity in selected heavyweights, dealers said.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

22h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

23h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...